1. Home
  2. CYD vs AUPH Comparison

CYD vs AUPH Comparison

Compare CYD & AUPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo China Yuchai International Limited

CYD

China Yuchai International Limited

HOLD

Current Price

$49.30

Market Cap

2.1B

Sector

Industrials

ML Signal

HOLD

Logo Aurinia Pharmaceuticals Inc

AUPH

Aurinia Pharmaceuticals Inc

HOLD

Current Price

$16.44

Market Cap

2.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CYD
AUPH
Founded
1951
1993
Country
Singapore
Canada
Employees
N/A
N/A
Industry
Industrial Machinery/Components
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.1B
2.0B
IPO Year
1998
2014

Fundamental Metrics

Financial Performance
Metric
CYD
AUPH
Price
$49.30
$16.44
Analyst Decision
Strong Buy
Buy
Analyst Count
1
4
Target Price
$60.00
$17.25
AVG Volume (30 Days)
204.9K
1.1M
Earning Date
02-24-2026
05-07-2026
Dividend Yield
1.32%
N/A
EPS Growth
N/A
5075.00
EPS
N/A
0.25
Revenue
N/A
$283,055,000.00
Revenue This Year
$15.11
$17.54
Revenue Next Year
$8.67
$15.74
P/E Ratio
$32.71
$65.72
Revenue Growth
N/A
20.38
52 Week Low
$21.10
$7.29
52 Week High
$61.48
$16.88

Technical Indicators

Market Signals
Indicator
CYD
AUPH
Relative Strength Index (RSI) 44.18 59.45
Support Level $35.70 $14.60
Resistance Level $56.55 $16.88
Average True Range (ATR) 3.36 0.52
MACD -1.11 0.07
Stochastic Oscillator 16.79 80.92

Price Performance

Historical Comparison
CYD
AUPH

About CYD China Yuchai International Limited

China Yuchai International Ltd is a Bermuda holding company that is a subsidiary of Singapore-based Hong Leong Asia. China Yuchai International operates through its majority-owned subsidiary Guangxi Yuchai Machinery Company, a China-based company that manufactures, assembles, and distributes diesel engines for various vehicles including trucks, buses, and cars, as well as construction and agricultural, marine, and power-generation equipment. It generates the majority of its sales from the Chinese market.

About AUPH Aurinia Pharmaceuticals Inc

Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing aritinercept, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.

Share on Social Networks: